{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:05:04Z","timestamp":1762981504561,"version":"build-2065373602"},"reference-count":28,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Key Clinical Specialties Program of Beijing, China","award":["no number"],"award-info":[{"award-number":["no number"]}]},{"name":"National Key Technologies R&D Program for the 13th Five-year Plan","award":["2017ZX10202101"],"award-info":[{"award-number":["2017ZX10202101"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,11,8]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Current antiretroviral regimens have, for the most part, achieved optimal antiretroviral efficacy and tolerability, transforming HIV infection from a deadly disease into a manageable chronic condition. However, adherence to daily oral drug intake remains an issue, as it is the most important determinant for sustained viral suppression and prevention of the emergence of drug-resistant viral strains. The long-acting injection antiretroviral cabotegravir and rilpivirine combination, a novel drug delivery approach, is about to revolutionise the therapy for people living with HIV. In this protocol, we aim to generate a clinically useful summary of the interventions based on their efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We searched the literature for eligible studies published from inception up to 16 August 2022 through PubMed, EMBASE, Cochrane Library, Scopus and ClinicalTrials.gov. Two methodologically trained researchers will select the qualified studies for data extraction independently. Cochrane Risk of Bias tool will be used to assess the risk of bias in included studies. Statistical heterogeneity will be computed by Cochrane X<jats:sup>2<\/jats:sup> and I<jats:sup>2<\/jats:sup> tests. Sensitivity analysis will be conducted to evaluate the stability of the results. Publication biases will be evaluated by Begg\u2019s and Egger\u2019s tests. The quality of evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluation system. The RevMan V.5.3 and Stata V.14.0 software will be applied for statistical analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>Ethical approval will not be required for this systematic review because the data used are not linked to the individual patient. The results of this review will be disseminated by being published in a peer-reviewed journal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42022310414<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063089","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T10:42:38Z","timestamp":1672051358000},"page":"e063089","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9299-3614","authenticated-orcid":false,"given":"Yuan-ni","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianfeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China"},{"name":"Tsinghua-Peking Center for Life Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China"},{"name":"Tsinghua-Peking Center for Life Sciences, Beijing, China"},{"name":"Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"2025101810162586000_12.12.e063089.1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2706.210284"},{"key":"2025101810162586000_12.12.e063089.2","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.19.1.21133","article-title":"The UNAIDS 90-90-90 target: a clear choice for ending AIDS and for sustainable health and development","volume":"19","author":"Sidib\u00e9","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2025101810162586000_12.12.e063089.3","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS) . Global AIDS update 2020\u2014Seizing the moment: tackling entrenched inequalities to end epidemics. Geneva, Switzerland: Google Scholar, 2020."},{"key":"2025101810162586000_12.12.e063089.4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00831"},{"key":"2025101810162586000_12.12.e063089.5","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS) . The gap report. Geneva, Switzerland: Google Scholar, 2014."},{"key":"2025101810162586000_12.12.e063089.6","unstructured":"Council A . Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Google Scholar, 2021."},{"key":"2025101810162586000_12.12.e063089.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable art: a qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"Kerrigan","year":"2018","journal-title":"PLoS One"},{"key":"2025101810162586000_12.12.e063089.8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir370"},{"key":"2025101810162586000_12.12.e063089.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002183"},{"key":"2025101810162586000_12.12.e063089.10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10461-020-03055-1","article-title":"Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study","volume":"25","author":"de Los Rios","year":"2021","journal-title":"AIDS Behav"},{"key":"2025101810162586000_12.12.e063089.11","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192735"},{"key":"2025101810162586000_12.12.e063089.12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41687-019-0124-3","article-title":"A review of HIV-specific patient-reported measures of perceived barriers to antiretroviral therapy adherence: what themes are they covering?","volume":"3","author":"Engler","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"2025101810162586000_12.12.e063089.13","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.19.1.21166","article-title":"Barriers and facilitators of interventions for improving antiretroviral therapy adherence: a systematic review of global qualitative evidence","volume":"19","author":"Ma","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2025101810162586000_12.12.e063089.14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","article-title":"Advances in long-acting agents for the treatment of HIV infection","volume":"80","author":"Rana","year":"2020","journal-title":"Drugs"},{"key":"2025101810162586000_12.12.e063089.15","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000002"},{"key":"2025101810162586000_12.12.e063089.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0440-3"},{"key":"2025101810162586000_12.12.e063089.17","unstructured":"Therapeutics J . Edurant (rilpivirine) prescribing information. Google Scholar, 2019."},{"key":"2025101810162586000_12.12.e063089.18","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824d006e"},{"key":"2025101810162586000_12.12.e063089.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"2025101810162586000_12.12.e063089.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"2025101810162586000_12.12.e063089.21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-Acting injectable Cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 atlas and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025101810162586000_12.12.e063089.22","unstructured":"Overton ET , Richmond GJ , Rizzardini G . Cabotegravir + rilpivirine every 2 months is NONINFERIOR to monthly: ATLAS-2M study. presented at: conference on retroviruses and opportunistic infections, 2020."},{"key":"2025101810162586000_12.12.e063089.23","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-Acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3B, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"2025101810162586000_12.12.e063089.24","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2025101810162586000_12.12.e063089.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025101810162586000_12.12.e063089.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025101810162586000_12.12.e063089.27","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025101810162586000_12.12.e063089.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:16:34Z","timestamp":1760807794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,26]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/bmjopen-2022-063089"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063089","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}